Volume 14, Number 1—January 2008
Research
Short- and Long-term Effects of Bacterial Gastrointestinal Infections
Anders Ternhag*
, Anna Törner†, Åke Svensson†‡, Karl Ekdahl*§, and Johan Giesecke*§
, Anna Törner†, Åke Svensson†‡, Karl Ekdahl*§, and Johan Giesecke*§
Table 4
Complications associated with gastroenteritis, 1 year postinfection, among 101,855 patients with bacterial gastrointestinal infection, Sweden, 1997−2004*
| Disease | Infecting organism | Obs | Exp | SIR | 95% CI |
|---|---|---|---|---|---|
| Digestive system | |||||
| Crohn’s disease | Campylobacter spp. | 27 | 17.1 | 1.6 | 1.0–2.3 |
| Salmonella spp. | 14 | 10.3 | 1.4 | 0.8–2.3 | |
| Shigella spp. | 1 | 1.1 | 0.9 | 0.02–5.2 | |
| Yersinia spp. | 2 | 1.1 | 1.8 | 0.2–6.4 | |
| Ulcerative colitis | Campylobacter spp. | 42 | 14.8 | 2.8 | 2.0–3.8 |
| EHEC | 1 | 0.1 | 6.8 | 0.2–37.7 | |
| Salmonella spp. | 29 | 9 | 3.2 | 2.2–4.6 | |
| Yersinia spp. | 3 | 1 | 2.9 | 0.6–8.5 | |
| Other specified/unspecified noninfective gastroenteritis and colitis | Campylobacter spp. | 37 | 14.9 | 2.5 | 1.8–3.4 |
| Salmonella spp. | 30 | 9.2 | 3.3 | 2.2–4.6 | |
| Yersinia spp. | 10 | 1.3 | 7.6 | 3.7–14.0 | |
| Irritable bowel syndrome | Campylobacter spp. | 15 | 5 | 3.0 | 1.7–5.0 |
| Salmonella spp. | 5 | 3 | 1.7 | 0.5–3.9 | |
| Yersinia spp. | 3 | 0.4 | 7.8 | 1.6–22.9 | |
| Intestinal malabsorption | Salmonella spp. | 1 | 0.6 | 1.7 | 0.04–9.3 |
| Yersinia spp. |
1 |
0.1 |
7.9 |
0.2–43.7 |
|
| Musculoskeletal system | |||||
| Postdysenteric arthropathy, Reiter disease, other reactive arthropathies | Campylobacter spp. | 15 | 2.4 | 6.3 | 3.5–10.4 |
| Salmonella spp. | 27 | 1.5 | 18.2 | 12.0–26.5 | |
| Shigella spp. | 2 | 0.1 | 13.4 | 1.6–48.4 | |
| Yersinia spp. | 9 | 0.2 | 47.0 | 21.5–89.2 | |
| Rheumatoid arthritis | Campylobacter spp. | 22 | 22.5 | 1.0 | 0.6–1.5 |
| EHEC | 1 | 0.2 | 5.8 | 0.2–32.1 | |
| Salmonella spp. | 9 | 14.7 | 0.6 | 0.3–1.2 | |
| Shigella spp. | 1 | 1.2 | 0.8 | 0.02–4.7 | |
| Yersinia spp. | 3 | 1.5 | 2.0 | 0.4–5.7 | |
| Other arthritis | Campylobacter spp. | 8 | 3.8 | 2.1 | 0.9–4.2 |
| Salmonella spp. | 4 | 2.5 | 1.6 | 0.4–4.1 | |
| Shigella spp. | 1 | 0.2 | 4.3 | 0.1–24.1 | |
| Yersinia spp. | 1 | 0.4 | 2.4 | 0.06–13.4 | |
| Other necrotizing vasculopathies (Goodpasture syndrome, TTP, Wegener granulomatosis, giant cell arteritis) | Campylobacter spp. | 10 | 3.3 | 3.1 | 1.5–5.6 |
| EHEC | 0 | <0.05 | 32.8 | 0.8–183.0 | |
| Salmonella spp. | 1 | 2.1 | 0.5 | 0.01–2.7 | |
| Systemic lupus erythematosus | Campylobacter spp. | 5 | 3.4 | 1.5 | 0.5–3.4 |
| Salmonella spp. | 2 | 2.1 | 1.0 | 0.1–3.5 | |
| Systemic sclerosis | Campylobacter spp. | 2 | 1.7 | 1.2 | 0.2–4.4 |
| Salmonella spp. | 3 | 1.1 | 2.8 | 0.6–8.1 | |
| Other systemic involvement of connective tissue (Sjögren syndrome, mixed connective tissue disease, polymyalgia rheumatica) | Campylobacter spp. | 12 | 5 | 2.4 | 1.2–4.2 |
| Salmonella spp. | 4 | 3.1 | 1.3 | 0.4–3.3 | |
| Shigella spp. | 1 | 0.2 | 4.2 | 0.1–23.3 | |
| Ankylosing spondylitis | Campylobacter spp. | 2 | 1.1 | 1.8 | 0.2–6.4 |
| Salmonella spp. | 1 | 0.7 | 1.5 | 0.04–8.1 |
*Obs, observed number of cases; Exp, expected number of cases; SIR, standardized incidence ratio; CI, confidence interval; EHEC, enterohemorrhagic Escherichia coli.; TTP, thrombotic thrombocytopenic purpura.
Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.